Neuphoria Therapeutics Inc (NEUP) - Total Liabilities
Based on the latest financial reports, Neuphoria Therapeutics Inc (NEUP) has total liabilities worth $6.90 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Neuphoria Therapeutics Inc equity growth rate to track the company's year-over-year net asset growth rate.
Neuphoria Therapeutics Inc - Total Liabilities Trend (1999–2025)
This chart illustrates how Neuphoria Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Neuphoria Therapeutics Inc to measure how efficiently the company converts operating cash flow to free cash.
Neuphoria Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Neuphoria Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
VRX Silica Ltd
AU:VRX
|
Australia | AU$761.02K |
|
Getabec Public Company Limited
BK:GTB
|
Thailand | ฿246.43 Million |
|
Efficient E Solutions Bhd
KLSE:0064
|
Malaysia | RM11.79 Million |
|
YSX Tech. Co., Ltd Class A Ordinary Shares
NASDAQ:YSXT
|
USA | $16.96 Million |
|
STS Group AG
XETRA:SF3
|
Germany | €177.70 Million |
|
CrystalGenomics Inc
KQ:083790
|
Korea | ₩124.24 Billion |
|
Spacenet Enterprises India Limited
NSE:SPCENET
|
India | Rs496.11 Million |
|
ClearSign Combustion Corporation
NASDAQ:CLIR
|
USA | $2.65 Million |
Liability Composition Analysis (1999–2025)
This chart breaks down Neuphoria Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Neuphoria Therapeutics Inc (NEUP) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neuphoria Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neuphoria Therapeutics Inc (1999–2025)
The table below shows the annual total liabilities of Neuphoria Therapeutics Inc from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $14.57 Million | +43.39% |
| 2024-06-30 | $10.16 Million | +114.21% |
| 2023-06-30 | $4.74 Million | -17.90% |
| 2022-06-30 | $5.78 Million | +15.34% |
| 2021-06-30 | $5.01 Million | -66.54% |
| 2020-06-30 | $14.97 Million | -40.58% |
| 2019-06-30 | $25.18 Million | -28.73% |
| 2018-06-30 | $35.34 Million | +5.43% |
| 2017-06-30 | $33.52 Million | -1.51% |
| 2016-06-30 | $34.04 Million | +19.40% |
| 2015-06-30 | $28.51 Million | +49.58% |
| 2014-06-30 | $19.06 Million | +71.11% |
| 2013-06-30 | $11.14 Million | +109.16% |
| 2012-06-30 | $5.32 Million | -11.19% |
| 2011-06-30 | $6.00 Million | +16.63% |
| 2010-06-30 | $5.14 Million | +5.63% |
| 2009-06-30 | $4.87 Million | -25.04% |
| 2008-06-30 | $6.49 Million | -5.76% |
| 2007-06-30 | $6.89 Million | +5.88% |
| 2006-06-30 | $6.51 Million | +33.95% |
| 2005-06-30 | $4.86 Million | +15.21% |
| 2004-06-30 | $4.22 Million | +6.87% |
| 2003-06-30 | $3.95 Million | +19.80% |
| 2002-06-30 | $3.29 Million | +904.77% |
| 2001-06-30 | $327.78K | +123.24% |
| 2000-06-30 | $146.83K | -70.98% |
| 1999-06-30 | $506.00K | -- |
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disord… Read more